<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03895138</url>
  </required_header>
  <id_info>
    <org_study_id>20164</org_study_id>
    <secondary_id>5R21EB018052</secondary_id>
    <nct_id>NCT03895138</nct_id>
  </id_info>
  <brief_title>Trial to Investigate the in Silico Optimization of Insulin Treatments</brief_title>
  <official_title>A Feasibility Randomized Control Trial to Investigate the in Silico Optimization of Insulin Treatments</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute for Biomedical Imaging and Bioengineering (NIBIB)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess the performance of an in silico designed
      alternative protocol for control of stress hyperglycemia of inpatients treated for Coronary
      Artery Bypass Graft (CABG) or valve replacement surgery in the University of Virginia
      cardiothoracic ICU.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hypothesis of the study is that settings for the Glucommander protocol can be optimized
      in silico to achieve statistically improved low blood glucose index (LBGI) within the
      subpopulation of CABG and valve replacement patients who both receive Glucommander-based
      insulin therapy and meet Manufacturer's guidelines for starting with an initial multiplier
      value of .052, without risking clinically significant increase in exposure to hyperglycemia.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 19, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Subjects with CABG or open heart valve surgery will be enrolled in the study. They will be randomized to receive one of the following treatments:
Standard Glucommander Protocol (SGP)
Optimized Glucommander (OGM)</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exposure to risk of hypoglycemia</measure>
    <time_frame>24 hours of post-operative hospital stay</time_frame>
    <description>Exposure to risk of hypoglycemia as measured by the Low Blood Glucose Index (LBGI).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Exposure to risk of hypoglycemia</measure>
    <time_frame>48 hours of post-operative hospital stay</time_frame>
    <description>Exposure to risk of hypoglycemia as measured by the Low Blood Glucose Index (LBGI).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Coronary Artery Bypass</condition>
  <arm_group>
    <arm_group_label>Standard Glucommander Protocol (SGP)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CABG or open valve surgery patients treated for stress hyperglycemia with the standard Glucomander protocol according to the manufacturer recommendations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optimized Glucommander (OGM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CABG or open valve surgery patients treated for stress hyperglycemia with in silico optimized Glucomander protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Glucommander Protocol (SGP)</intervention_name>
    <description>Subjects receive standard Glucommander-based insulin therapy from the clinical staff of U.Va.'s cardiothoracic ICU and follow manufacturer's guidelines for starting with an initial multiplier value of .05.</description>
    <arm_group_label>Standard Glucommander Protocol (SGP)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Optimized Glucommander (OGM)</intervention_name>
    <description>The experimental arm of the study involves treating subjects with a lower initial multiplier (.02 versus .05), a higher set of BG thresholds (140-180 mg/dl vs 120-160) in the first eight (8) hours of care for avoidance of hypoglycemia in that time period, and a requirement for consistent hourly-or-faster sampling of BG (as opposed to the Glucommander recommendation which is dependent on the trajectory of BG and can sometimes allow intervals of two hours between samples). After the eight (8) hours, the Glucommander is set back to the standard protocol for the entire duration of the subject's post-operative hospital stay.</description>
    <arm_group_label>Optimized Glucommander (OGM)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients admitted for CABG and/or open heart valve surgery

          2. Must have a 0.05 initial multiplier setting for the Glucommander based on the
             manufacturers recommendations

          3. Age of 40-75, inclusive

        Exclusion Criteria:

          1. History of severe hypoglycemia within six months of hospital admission

          2. Currently undergoing dialysis or renal replacement therapy

          3. Women of childbearing potential

          4. Patients with endocarditis needing valve replacement

          5. Participation in another clinical trial at the time of screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Anna Buhle</last_name>
    <phone>4349898257</phone>
    <email>ab7ga@virginia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>leon farhi, PhD</last_name>
    <phone>4342966583</phone>
    <email>leon@virginia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Vrginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Buhle</last_name>
      <phone>434-989-8257</phone>
      <email>ab7ga@virginia.edu</email>
    </contact>
    <investigator>
      <last_name>Leon S Farhi, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anthony L McCall, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer Kirby, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anna Buhle</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gorav Ailawadi</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>J. Michael Cosner</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Kern</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Irving Kron</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephen Patek, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rachel Simon</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leora Yarboro, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 21, 2019</study_first_submitted>
  <study_first_submitted_qc>March 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2019</study_first_posted>
  <last_update_submitted>March 27, 2019</last_update_submitted>
  <last_update_submitted_qc>March 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Anthony McCall</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

